UBS analyst Andrew Peters said Esperion's updated development plans following the receipt of minutes from their end of phase 2 meeting with the FDA do not provide enough clarity to fully understand the path forward for ETC-1002. Investors will likely focus on updated language that suggests CVOT data "could" be required prior to approval, according to Peters, who said he would not be surprised to see near-term pressure on the stock. The update implies far greater uncertainty than was reflected in the firm's previous model, Peters tells investors, prompting him to lower his price target on Esperion shares to $69 from $133. However, the analyst keeps a Buy rating on shares, as he believes the stock should provide long-term upside.